Bacteria-killing viruses redirect vaccine immunity to destroy cancer
newscientist - Phages, viruses that infect bacteria, could be genetically manipulated to destroy cancerous cells using the immunity we have acquired from vaccines
AI Summary: Researchers show bacteriophages can redirect existing vaccine‑induced immunity to attack cancer cells, effectively hijacking antiviral immune memory to target tumours. This clever preclinical strategy repurposes phages as delivery vehicles and immunomodulators, opening a potential new class of off‑the‑shelf immunotherapies that could complement or bypass current T‑cell approaches — if it survives the usual valley of translation.
Cancer drug shortage renews calls for federal action
medicalxpress - Cancer doctors across the United States are running short of essential generic chemotherapy drugs, and some fear the squeeze could force widespread rationing, The New York Times reported.
AI Summary: Hospitals and oncology clinics are facing critical shortages of key chemotherapy agents, forcing clinicians to consider rationing or alternative regimens. The supply squeeze has reignited demands for federal intervention, supply‑chain fixes, and clearer contingency plans to protect patients who can’t exactly wait for bureaucratic miracles.
A Bridge to Nowhere? Medicare’s GLP-1 Coverage Expansion Requires A More Holistic Approach To Weight Management
Sandeep Palakodeti / medcitynews - For seniors, the change in policy will dramatically expand access to a revolutionary medication. But there are also significant risks.The post A Bridge to Nowhere? Medicare’s GLP-1 Coverage Expansion Requires A More Holistic Approach To Weight Management …
AI Summary: Medicare’s planned GLP‑1 coverage “bridge” has kicked off a scramble: policy analysts warn a narrow drug‑centric approach won’t fix weight management, while major retailers are rolling out programs and partnerships to plug access gaps. Expect patchwork solutions, eager pharmacies, and a chorus asking for a more holistic long‑term plan.
- Clinical risks and long-term effectiveness debate (5)
- Medicare Bridge rollout, eligibility and cost questions (5)
- Online prescribing, oversight and soaring GLP‑1 use (4)
- Retailers, pharmacies and manufacturers rush to plug access gaps (4)
- All Other Stories
Clinical risks and long-term effectiveness debate
Medicare Bridge rollout, eligibility and cost questions
Online prescribing, oversight and soaring GLP‑1 use
Retailers, pharmacies and manufacturers rush to plug access gaps
All Other Stories
Updated Long-Term Follow-Up From the Phase 1b BOT+BAL Study at ESMO GI 2026 – Agenus
oncodaily - Agenus shared a post on LinkedIn: “At ESMOGI26, Agenus will share updated long-term follow-up from the Phase 1b study evaluating botensilimab plus balstilimab (BOT+BAL) in patients with MSS metastatic colorectal […]
AI Summary: Updated follow‑up data presented for botensilimab plus balstilimab reveal meaningful and durable activity in microsatellite‑stable metastatic colorectal cancer, with especially encouraging outcomes in patients lacking active liver metastases. The Agenus combination, showcased at a major gastrointestinal oncology meeting, renews interest in immune strategies for historically refractory MSS disease.
- Agenus releases Phase 1b three-year BOT+BAL survival data (2)
- Clinical and community reaction: experts weigh in on BOT+BAL (3)
- ESMO GI: BOT+BAL benefits in patients without active liver metastases (3)
- All Other Stories